Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study
Tempei Otsubo,1 Yoshinori Watanabe,2,3 Seiji Hongo,3 Mikichika Inoue,4 Kimiko Akimoto,4 Ken Murakami,5 Ryutaro Takahashi,6 Toshiaki Kikuchi7 1Department of Psychiatry, Tokyo Women’s Medical University Medical Center East, Tokyo, Japan; 2Himorogi Psychiatric Institute, Tokyo, Japan; 3Nanko...
Guardado en:
Autores principales: | Otsubo T, Watanabe Y, Hongo S, Inoue M, Akimoto K, Murakami K, Takahashi R, Kikuchi T |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/20da93dc94904d95baef838f0972b627 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi T, et al.
Publicado: (2017) -
Formulation and Development of Oral Fast-Dissolving Films Loaded with Nanosuspension to Augment Paroxetine Bioavailability: In Vitro Characterization, Ex Vivo Permeation, and Pharmacokinetic Evaluation in Healthy Human Volunteers
por: Ahmed Hassen Elshafeey, et al.
Publicado: (2021) -
Effects of personality on the association between paroxetine plasma concentration and response
por: Tomita T, et al.
Publicado: (2018) -
Encapsulated Escitalopram and Paroxetine Intranasal Co-Administration: In Vitro/In Vivo Evaluation
por: Soraia Silva, et al.
Publicado: (2021) -
A single‐center, open‐label, randomized cross‐over study to evaluate the pharmacokinetics and bioavailability of once‐daily prolonged‐release formulations of tacrolimus in de novo liver transplant recipients
por: Uta Herden, et al.
Publicado: (2021)